Health Canada has approved the first generic versions of Novo Nordisk's diabetes drug Ozempic, made by Dr. Reddy's Laboratories and Apotex, marking the first generics available in North America. These generics are currently only available in Canada, with seven more under review, and may lead to price reductions and revenue declines for Novo Nordisk internationally. The company expects a low single-digit impact and is using savings cards to retain customers. A significant price cut of 65% will be mandated once three generics enter the Canadian market, which Novo Nordisk is prepared to handle strategically. This development will serve as a test for generic competition against branded GLP-1 drugs.
Novo Resources Corp has completed the second tranche of an A$8.2 million placement, raising about C$1.93 million to accelerate drilling and exploration at its Pilbara and Victorian gold projects. The second tranche involved issuing units to Canadian ...
Novo Nordisk's investor relations highlighted that the launch of its oral semaglutide is progressing with dose escalation patterns differing from its injectable forms. Despite improved data capture at 65%, 90% of prescriptions are still paid out-of-p...
Novo Nordisk is gaining ground on Eli Lilly in the obesity drug market despite a 12.6% quarterly and 15% yearly drop in Ozempic sales to DKK 27.83 billion in Q1. The recent FDA approval of Wegovy HD, which matches Eli Lilly's Zepbound in weight-loss ...
Novo Resources Corp. has completed the second tranche of its placement, raising approximately C$1.93 million (A$1.95 million) through the issuance of common shares and options to investors in Canada and overseas. This follows shareholder approval at ...
CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound starting October 1 and begin covering Lilly's new obesity pill Foundayo from June 1 on its standard drug plans. This move balances coverage between Eli Lilly and Novo Nord...
